DDInter1613 DDInter704
Rofecoxib is used for the treatment of osteoarthritis, rheumatoid arthritis, acute pain in adults, and primary dysmenorrhea, as well as acute treatment of migraine attacks with or without auras. Rofecoxib is a solid. This compound belongs to the stilbenes. These are organic compounds containing a 1,2-diphenylethylene moiety. Stilbenes (C6-C2-C6 ) are derived from the common phenylpropene (C6-C3) skeleton building block. The introduction of one or more hydroxyl groups to a phenyl ring lead to stilbenoids. Rofecoxib has a half-life of 17 hours and its mean oral bioavailability at therapeutically recommended doses of 125, 25, and 50 mg is approximately 93%. The proteins that rofecoxib target include elastin and prostaglandin G/H synthase 2
Everolimus is a derivative of Rapamycin (sirolimus), and works similarly to Rapamycin as an mTOR (mammalian target of rapamycin) inhibitor. It is currently used as an immunosuppressant to prevent rejection of organ transplants. In a similar fashion to other mTOR inhibitors Everolimus' effect is solely on the mTORC1 protein and not on the mTORC2 protein.
Rofecoxib {u} may lead to a major life threatening interaction when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Everolimus
Rofecoxib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Apixaban
Apixaban {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Everolimus
Rofecoxib {u} may lead to a major life threatening interaction when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Pimecrolimus
Pimecrolimus {u} (Compound) resembles {v} (Compound) Everolimus
Rofecoxib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Gentamicin
Gentamicin {u} (Compound) downregulates {v} (Gene) CNDP2
CNDP2 {u} (Gene) is downregulated by {v} (Compound) Everolimus
Rofecoxib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Apixaban
Apixaban {u} (Compound) causes {v} (Side Effect) Nausea
Nausea {u} (Side Effect) is caused by {v} (Compound) Everolimus
Rofecoxib {u} may lead to a major life threatening interaction when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Temsirolimus {u} (Compound) resembles {v} (Compound) Everolimus
Rofecoxib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Gentamicin
Gentamicin {u} may lead to a major life threatening interaction when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Everolimus
Rofecoxib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nateglinide
Nateglinide {u} (Compound) binds {v} (Gene) PPARG
PPARG {u} (Gene) is downregulated by {v} (Compound) Everolimus
Rofecoxib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Gentamicin
Gentamicin {u} (Compound) downregulates {v} (Gene) UBQLN2
UBQLN2 {u} (Gene) is upregulated by {v} (Compound) Everolimus
Rofecoxib {u} may lead to a major life threatening interaction when taken with {v} Sirolimus
Sirolimus {u} (Compound) binds {v} (Gene) FKBP1A
FKBP1A {u} (Gene) is bound by {v} (Compound) Everolimus
Rofecoxib may lead to a major life threatening interaction when taken with Sirolimus and Sirolimus (Compound) resembles Everolimus (Compound)
Rofecoxib may cause a moderate interaction that could exacerbate diseases when taken with Apixaban and Apixaban (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Everolimus (Compound)
Rofecoxib may lead to a major life threatening interaction when taken with Sirolimus and Sirolimus (Compound) resembles Pimecrolimus (Compound) and Pimecrolimus (Compound) resembles Everolimus (Compound)
Rofecoxib may cause a moderate interaction that could exacerbate diseases when taken with Gentamicin and Gentamicin (Compound) downregulates CNDP2 (Gene) and CNDP2 (Gene) is downregulated by Everolimus (Compound)
Rofecoxib may cause a moderate interaction that could exacerbate diseases when taken with Apixaban and Apixaban (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Everolimus (Compound)
Rofecoxib may lead to a major life threatening interaction when taken with Sirolimus and Sirolimus (Compound) resembles Temsirolimus (Compound) and Temsirolimus (Compound) resembles Everolimus (Compound)
Rofecoxib may cause a moderate interaction that could exacerbate diseases when taken with Gentamicin and Gentamicin may lead to a major life threatening interaction when taken with Sirolimus and Sirolimus (Compound) resembles Everolimus (Compound)
Rofecoxib may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide and Nateglinide (Compound) binds PPARG (Gene) and PPARG (Gene) is downregulated by Everolimus (Compound)
Rofecoxib may cause a moderate interaction that could exacerbate diseases when taken with Gentamicin and Gentamicin (Compound) downregulates UBQLN2 (Gene) and UBQLN2 (Gene) is upregulated by Everolimus (Compound)
Rofecoxib may lead to a major life threatening interaction when taken with Sirolimus and Sirolimus (Compound) binds FKBP1A (Gene) and FKBP1A (Gene) is bound by Everolimus (Compound)